Improving Detection and Management of ATTR-CM Through Pharmacy Care

Clinical pharmacists have a critical, multifaceted role in improving the detection and management of transthyretin amyloid cardiomyopathy (ATTR-CM). In a Pharmacy Times Clinical Forum discussion, moderator Stormi Gale, PharmD, BCPS, BCCP, FHFSA, a cardiology clinical pharmacy specialist in the cardiovascular intensive care unit at Atrium Health Carolinas Medical Center, Wingate University School of Pharmacy, emphasizes how pharmacists are often the most accessible health care professionals to patients and are key in proactively detecting ATTR-CM through “red flags,” addressing medication access, and helping patients overcome operational challenges and hurdles during the treatment journey.

What is ATTR-CM?

ATTR-CM is caused by the destabilization of a transport protein called transthyretin (TTR), which normally carries thyroxine and retinol-binding protein through the blood. In patients with this disease, the TTR protein becomes unstable and misfolds into tetramers, which further break down into monomers. These monomers then aggregate into fibrils that deposit into the myocardium (heart muscle). Over time, as these fibrils continue to accumulate, they lead to restrictive cardiomyopathy and diastolic dysfunction.

ATTR-CM presents with a combination of cardiac and extracardiac symptoms that often overlap with more common conditions such as heart failure with preserved ejection fraction (HFpEF) or hypertensive heart disease. Common cardiac symptoms of ATTR-CM include dyspnea (shortness of breath), edema (swelling), and arrhythmias, particularly atrial fibrillation. As amyloid fibrils deposit in the heart muscle, patients may also develop restrictive cardiomyopathy and diastolic dysfunction, which contribute to worsening cardiac function and symptom burden.

“A lot of times, you see these patients because they came to you for just management of heart failure or management of atrial fibrillation. But there [are] also some extracardiac findings, because these fibrils don't necessarily only deposit into the myocardium. They can also deposit into other areas,” Gale said. “When they do this, you can see things like bilateral carpal tunnel syndrome, spinal stenosis, bicep tendon rupture…. These orthopedic issues are huge red flags if you have a patient who you're managing for heart failure who has these in their past medical history.”

Several clinical indicators may also suggest a higher risk for ATTR-CM. One major clue is intolerance to guideline-directed medical treatment (GDMT), particularly an inability to initiate or uptitrate standard heart failure medications because of unexpected hypotension. A history of transcatheter aortic valve replacement or aortic stenosis may also increase suspicion, as may evidence of left ventricular hypertrophy identified through echocardiogram or cardiac MRI. Patients who frequently “bounce back” to the hospital for heart failure despite treatment with standard therapies (eg, sodium-glucose cotransporter 2 [SGLT2] inhibitors or mineralocorticoid receptor antagonists [MRAs]) may warrant further evaluation. Additionally, a family history of the condition may prompt earlier screening.

Although the prevalence of ATTR-CM may be higher than currently documented, the disease is frequently missed because health care professionals may attribute symptoms to more common conditions or fail to recognize the connection between cardiac findings and earlier orthopedic manifestations. Underdiagnosis and misdiagnosis of these more common conditions can delay appropriate treatment.

Current Treatment Landscape

Management of ATTR-CM has evolved significantly with the implementation of disease-modifying therapies. These include the 3 FDA-approved medications—tafamidis (Vyndamax; Pfizer), acoramidis (Attruby; BridgeBio Pharma), and vutrisiran (Amvuttra; Alnylam Pharmaceuticals)—all of which aim to stabilize the TTR protein or reduce its production, the underlying pathology of ATTR-CM. Specifically, these 3 agents manage symptomatic patients who are not in the very advanced stages of disease.

Tafamidis and Clinical Trial Data Supporting Its Efficacy

Tafamidis is a TTR stabilizer that works by selectively binding TTR tetramers and preventing their dissociation into monomers, thereby inhibiting misfolding and amyloid fibril formation in the myocardium.

The discussion highlighted several clinical and operational advantages associated with tafamidis. As an oral medication taken at home, it is considerably easier to manage operationally than injectable therapies, such as vutrisiran, which require coordination with infusion centers and more complex scheduling logistics. However, despite being preferred by many clinicians, insurance coverage remains the predominant factor influencing its use.

The pivotal evidence base for tafamidis in ATTR-CM comes from the phase 3 ATTR-ACT trial (NCT01994889),¹ a multicenter, international, 3-arm, placebo-controlled, double-blind, randomized trial enrolling 441 patients aged 18 to 90 years in a 2:1:2 ratio to receive tafamidis 80 mg, tafamidis 20 mg, or placebo. The study ran for 30 months and included 335 patients with wild-type ATTR-CM and 106 with hereditary ATTR-CM. The primary end point was the composite of all-cause death and cardiovascular-related hospitalizations from baseline to 30 months, combined across the 2 tafamidis arms (N = 264) and compared with placebo (N = 177).^1,2

Tafamidis significantly reduced the primary composite end point, with a win ratio of approximately 1.70 (95% CI, 1.26-2.29; P = .0006) using the Finkelstein–Schoenfeld method. All-cause mortality was approximately 29.5% in the tafamidis group compared with 42.9% in the placebo group, with cardiovascular-related hospitalizations occurring in 52.3% vs 60.5% of patients, respectively. Specifically, the HR for all-cause mortality was 0.70 (95% CI, 0.51-0.96), and the relative risk ratio for cardiovascular hospitalizations was 0.68 (95% CI, 0.56-0.81). Notably, the mortality benefit did not achieve statistical significance until 15 to 18 months into the trial, which is consistent with tafamidis’s mechanism of gradually stabilizing TTR and curbing amyloid fibril deposition over time.²

Beyond survival and hospitalization, secondary end points reflected meaningful clinical benefit. At month 30, patients treated with tafamidis had better overall 6-minute walk test distance, NT-proBNP concentration, patient global assessment of overall health score, and Kansas City Cardiomyopathy Questionnaire Overall Summary score than those treated with placebo. At baseline, participants could walk approximately 350 meters in 6 minutes. Although walking distance declined in both groups over 30 months, the group receiving tafamidis 80 mg declined meaningfully less than the placebo group.²

Echocardiographic data also showed benefit: Significant changes from baseline to month 30 were observed in left ventricular global longitudinal strain (P = .005), septal E/e′ (P = .01), and lateral E/e′ (P = .006) with tafamidis treatment.³

Across prespecified subgroups, the benefit was similar regardless of dose and whether patients had hereditary or wild-type ATTR-CM. An important exception was identified in more advanced disease: In patients with New York Heart Association class III heart failure, rates of cardiovascular-related hospitalizations were higher in the tafamidis group than in the placebo group, which remains a clinically important consideration when initiating therapy in advanced-stage patients. Consistent with this, the benefit was greatest in patients with earlier-stage disease, underscoring the importance of early diagnosis and prompt treatment initiation. Safety was favorable throughout: The frequency of adverse events in patients treated with tafamidis was similar to that seen with placebo.^2,3

A separate analysis from ATTR-ACT and its long-term extension addressed the dose question directly. It demonstrated an approximate 30% relative reduction in the risk of death (P = .0374) among patients initially treated with tafamidis meglumine (Vyndaqel; Pfizer) 80 mg, followed by transition to tafamidis 61 mg, compared with those initially treated with tafamidis meglumine 20 mg. After adjusting for covariates including age, biomarkers, and functional capacity, the risk reduction increased to 43% (P < .05) for the 80-mg/61-mg dose vs the 20-mg dose. This is the foundation for 80 mg/61 mg being the approved and recommended therapeutic dose.⁴

Following completion of ATTR-ACT, patients were eligible to enroll in an open-label, 60-month long-term extension (LTE) study to evaluate additional safety data and allow continued treatment, with the protocol later amended to permit transitioning to tafamidis 61 mg. A post hoc interim analysis of the LTE, published in Circulation: Heart Failure, compared patients who had received continuous tafamidis from the outset against those who received placebo during ATTR-ACT before crossing over to active treatment. The preliminary 5-year survival rate was 53% with continuous tafamidis meglumine/tafamidis treatment vs 32% with placebo crossover to tafamidis meglumine/tafamidis, with no new safety concerns observed. It bears noting that this analysis was nonprespecified, not powered for formal hypothesis testing on all-cause mortality, and should be interpreted accordingly, though the magnitude of the survival difference is clinically compelling.⁴

In terms of regulatory status, tafamidis 61 mg received FDA approval in May 2019 and is indicated for the treatment of cardiomyopathy in adults with wild-type or hereditary transthyretin-mediated amyloidosis to reduce cardiovascular mortality and cardiovascular-related hospitalizations, making it the only approved once-daily single-capsule formulation for this indication.⁵

Selecting Appropriate Treatments for Patients

For this patient population, therapy selection among these agents is rarely driven by clinical superiority data, as strong head-to-head comparisons are currently lacking. Because tafamidis was the first drug available for this condition, many physicians are most familiar with it and often consider it their first-line treatment choice for patients. Instead, treatment decisions are primarily influenced by practical considerations such as insurance coverage, which is often the predominant factor.

“From our clinic standpoint, [treatment is] predominantly [dependent on] what is going to be covered. We have even had issues this past year where coverage has changed, where all these patients were all on tafamidis, and then it's no longer covered. We had to switch them over to acoramidis,” said Kaitlyn Pinkos, PharmD, BCCP, a clinical pharmacy specialist at NewYork-Presbyterian Hospital. “Coverage has been the predominant factor [in] deciding which route to go. Medicare currently is still paying for one of the tafamidis, acoramidis, and vutrisiran…we are doing both of those therapies for our Medicare patients. But [coverage is] our main deciding factor.”

Route of administration also plays a role in therapy selection, as tafamidis and acoramidis are oral therapies taken at home, whereas vutrisiran requires administration in a clinical setting, often through an infusion center or specialized injection clinic.

Because these medications are high-cost, limited-distribution therapies with 5-figure price tags, specialty pharmacists play an essential role in patient care. They are heavily involved in navigating prior authorizations, conducting benefits investigations, and identifying patient assistance programs to help ensure treatment affordability and access.

Management of ATTR-CM often requires modifications to standard GDMT, as patients with amyloidosis frequently do not tolerate traditional heart failure medications. Clinicians commonly deprescribe β-blockers due to poor tolerance, whereas supportive therapies such as SGLT2 inhibitors and MRAs are often used to manage heart failure symptoms. Loop diuretics also remain important for volume control.

Several operational and clinical challenges continue to complicate ATTR-CM management. Although some centers previously used combination therapy, such as an oral stabilizer paired with an injectable agent, recent guidance suggests there is no clear role for combination therapy, prompting many payers to stop covering dual-agent approaches. In the inpatient setting, most hospital pharmacies do not stock these medications because of their high cost, requiring patients to bring their own home supply or temporarily hold therapy during hospitalization if access is unavailable. Additionally, there are often substantial delays between diagnosis and treatment initiation, ranging from a few weeks to as long as 3 months, largely due to the complexity of diagnostic evaluations and the insurance approval process.

Overcoming Hurdles During Treatment

Health care providers face a multifaceted set of challenges in treating patients with ATTR-CM, ranging from the initial identification of the disease to navigating high-cost medication access and managing operational hurdles within hospital systems.

During the conversation, one of the primary challenges emphasized by the experts is delayed detection and diagnosis, which can take years from symptom onset. Because some common symptoms overlap with more common conditions (eg, HFpEF, hypertensive heart disease), ATTR-CM is difficult to recognize early. Additionally, because the disease presents with heterogeneous symptoms, patients are often treated across specialty silos, with orthopedists addressing carpal tunnel syndrome, neurologists managing polyneuropathy, and cardiologists treating heart failure. These specialists may not communicate or “connect the dots” to suspect amyloidosis.

Lack of awareness also contributes to delays, as many general cardiologists and primary care providers may not have the mental checklists needed to recognize ATTR-CM, instead focusing on more common cardiovascular metrics such as low-density lipoprotein levels. Access to diagnostic testing further complicates timely identification, as smaller institutions may lack noninvasive imaging tools, such as pyrophosphate scans or cardiac MRI, which are more readily available at large academic centers with dedicated amyloid specialists.

“I have a checklist of 3 or 4 things [that I look for in a patient], and it's like my spidey senses go off,” Glenn Harrington, PharmD, FACC, FHFSA, BCCP, CPP, HFCert, a cardiology pharmacist at Novant Health Heart & Vascular Institute, said during the discussion. “And I'll message different people [on the care team], ‘Hey, did you think about [ATTR-CM]?’ And a lot of times [they’ll say], ‘Oh, I hadn’t thought about that.’”

After diagnosis, financial and insurance barriers become a major challenge because treatment costs are frequently described as, what the experts called, “5-figure expenses.” In many cases, insurance coverage dictates treatment selection more than clinical preference, with providers often prescribing the 3 FDA-approved therapies that are preferred by the patient’s insurance plan. The administrative burden of securing these therapies is substantial and often requires significant involvement from specialty pharmacists who handle complex prior authorizations, benefits investigations, and patient assistance programs. Although some clinicians believe targeting multiple disease mechanisms through combination therapy may be beneficial, newer consensus guidelines indicate there is no clear role for combination therapy, prompting many payers to discontinue coverage for dual-agent treatment approaches.

Operational and institutional barriers within health care systems also complicate patient management. Electronic medical record systems, including platforms such as Cerner, are often described as difficult to use when building automated scoring tools or alerts to identify high-risk patients. In the inpatient setting, most hospital pharmacies do not stock these costly, limited-distribution medications, meaning patients are often required to bring their own home supply. If they cannot, clinicians may have no choice but to hold therapy for the duration of hospitalization, which can sometimes last weeks. Injectable therapies such as vutrisiran add another layer of complexity because they require coordination with infusion centers and the use of detailed “therapy plans” in the electronic health record, processes that many cardiologists find cumbersome and non–user friendly. Geographic barriers can also affect access to care, particularly for patients in rural areas who may struggle to travel to urban centers for regular injections.

“Sometimes there [are] big delays [with treatment], and I'm writing [to other team members], ‘What’s going on?’ And they [answer], ‘Oh, they asked for more information. We're still working on it,’” said Vicki Groo, PharmD, BCCP, a cardiology clinical pharmacist at the University of Illinois Chicago. “Or, sometimes specialty pharmacy gets overloaded…they're doing drugs for everything, so they get overloaded with some things and they get behind on [what we ask for], or whatever the case may be.”

Finally, ATTR-CM presents unique clinical management challenges that often require deviation from standard heart failure protocols. Unlike patients with traditional heart failure, individuals with ATTR-CM frequently do not tolerate standard GDMT, particularly β-blockers, which often must be discontinued. In addition, many clinics lack access to dedicated genetic counselors, creating challenges in hereditary testing and navigating the sensitive process of screening family members who may also be at risk for the disease.

How the Pharmacist Is Involved in Helping Treat Patients With ATTR-CM

In ambulatory clinics, pharmacists are key when managing the unique needs of patients with amyloidosis, which often differ substantially from traditional heart failure management protocols. Additionally, they are imperative in maintaining continuity of care during hospitalization. As liaisons between outpatient and inpatient settings, they often help address challenges related to specialty medications, ensuring patients can continue their home supply whenever possible, particularly because most hospital pharmacies do not routinely stock these therapies.

In addition to clinical management, pharmacists help bridge gaps in specialized knowledge through education directed toward both patients and the broader medical team. They frequently serve as multidisciplinary liaisons, educating orthopedic surgeons, neurologists, and primary care providers about the red flags of ATTR-CM that may prompt earlier referral to cardiology. Pharmacists also contribute to professional education by leading initiatives—such as cardiology “boot camps,” as Groo described—for new fellows and grand rounds for internal medicine teams to improve institutional awareness of amyloidosis.

Patient counseling is another critical component of the pharmacist’s role. Pharmacists often provide intensive 1:1 education to help patients better understand disease progression, the importance of medication adherence, and the risks and benefits associated with newer therapies. The experts also emphasized that it is important to take advantage of resources when possible, especially when it comes to optimizing workflow and mitigating delays in treatment.

“Leveraging our specialty pharmacy to take the workload off of the providers in clinics and just [making] it as easy as possible to recognize a patient [who] needs a medication [and to] prescribe the medication—it all just kind of happens behind the scenes,” Harrington explained. “[At my clinic], we have actually made it so seamless with our specialty pharmacy that we don't even see all these patients in the clinic. If the provider is comfortable and they've got the diagnosis, they'll send the prescription, and then the specialty pharmacist will communicate back with the provider if there is anything missing. But trying to automate as much as you can just to minimize that burden [is important], because that's where patients fall through the cracks.”

REFERENCES

1. Safety and efficacy of tafamidis in patients with transthyretin cardiomyopathy (ATTR-ACT). ClinicalTrials.gov. Updated April 24, 2019. Accessed June 4, 2026. https://clinicaltrials.gov/study/NCT01994889

2. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016. doi:10.1056/NEJMoa1805689

3. Shah SJ, Fine N, Garcia-Pavia P, et al. Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: A post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol. 2024;9(1):25–34. doi:10.1001/jamacardio.2023.4147

4. Elliott P, Drachman BM, Gottlieb SS, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15(1):e008193. doi:10.1161/CIRCHEARTFAILURE.120.008193

5. US FDA approves Vyndaqel and Vyndamax for use in patients with transthyretin amyloid cardiomyopathy, a rare and fatal disease. News release. Pfizer. May 6, 2019. Accessed June 4, 2026. https://tinyurl.com/mrycn3um